 | | | Vol. 12.37 – 2 October, 2020 |
|
|
|
| Scientists used pooled and arrayed Cas9 ribonucleoprotein screens to identify transcription factors that regulate critical proteins in primary human regulatory T cells under basal and proinflammatory conditions.
[Nature Immunology] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators showed that BATF3 was expressed transiently within the first days after T cell priming and had long-lasting T cell–intrinsic effects.
[Nature Immunology] |
|
|
|
| The authors showed that in vivo IRX4204 was compared favorably with FK506 in abrogating acute graft-versus-host disease, which was associated with inhibiting allogeneic donor T cell proliferation, reducing T helper 1 differentiation and promoting regulatory T cell generation.
[Blood] |
|
|
|
| Scientists report a synthetic immunology approach using a photo-activatable immune modulator to increase Th17 cell differentiation on demand with spatial and temporal precision. They developed a latent agonist that, upon photochemical activation, releases a small-molecule ligand that targets the aryl hydrocarbon receptor and ultimately induces Th17 cell differentiation.
[Journal of the American Chemical Society] |
|
|
|
| Researchers performed immune profiling of samples from tumor bearing mice and cancer patients to demonstrate differential expression of inducible co-stimulatory receptor (ICOS) in immune T cell subsets in different tissues. ICOS expression was higher on intratumoral TReg than on effector CD8 T cells.
[Cancer Immunology Research] |
|
|
|
| The authors describe a mechanism underlying the regulation of programmed cell death-1 (PD-1) at the mRNA level and demonstrated its impact on T-cell dysfunction. Transcriptomic analysis identified a correlation between transforming growth factor beta 1 and PDCD1 in clear cell renal cell carcinoma samples.
[Cancer Immunology Research] |
|
|
|
| Scientists showed that microparticle-mediated intratumoral delivery of NAMPT inhibitor GMX1778 induced specific immunological changes in the tumor microenvironment of murine glioblastoma, characterized by upregulation of immune checkpoint PD-L1, recruitment of CD3+, CD4+, and CD8+ T cells.
[Cancer Research] |
|
|
|
| Researchers showed in mice that activation of canonical Gli-dependent Hedgehog signaling by Gli1 gene transfer was sufficient to recover salivary function impaired by irradiation.
[Cancer Research] |
|
|
|
| Pterostilbene (PSB) was found to exert the strongest inhibitory effect among all tested resveratrol derivatives on dendritic cell‐mediated T cell proliferation; moreover, PSB treatment decreased the Th1 and Th17 populations and increased the regulatory T cell population.
[FASEB Journal] |
|
|
|
| Researchers demonstrated the feasibility of perturbing protein synthesis in a mouse liver by targeting translation elongation factor 2 with RNAi. They were able to achieve over 90% knockdown efficacy and maintain it for two weeks effectively slowing down the rate of translation elongation.
[Scientific Reports] |
|
|
|
|
| The authors review the current information on the mode of action of the lineage-defining transcription factors Bcl6 and T-bet and how they act individually and in complex to govern CD4+ T-cell ontogeny.
[Cellular & Molecular Immunology] |
|
|
|
|
| Oncocyte Corporation announced that it has agreed to enter a licensing and collaboration agreement with Chronix Biomedical. Oncocyte is licensing Chronix’s patented CNI Monitor technology for the TheraSure™-CNI MONITOR clinical assay.
[Oncocyte Corporation] |
|
|
|
| Teneobio, Inc. and its affiliate TeneoTwo, Inc. announced that their investigational new drug application for TNB-486, a bispecific T-cell engaging antibody for the treatment of B-Cell Non-Hodgkin’s lymphoma was cleared for the initiation of Phase I clinical studies by the FDA on September 30, 2020.
[Teneobio, Inc.] |
|
|
|
|
| December 2 – December 4
Virtual |
|
|
|
|
|
| | Rheinische Friedrich-Wilhelms-Universität – Bonn, Germany |
|
|
|
| | STEMCELL Technologies – Flexible |
|
|
|
| | Texas Biomedical Research Institute – San Antonio, Texas, United States |
|
|
|
| | Purdue University – West Lafayette, Indiana, United States |
|
|
|
| | Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
